<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04932135</url>
  </required_header>
  <id_info>
    <org_study_id>EKNZ 2021-00422</org_study_id>
    <nct_id>NCT04932135</nct_id>
  </id_info>
  <brief_title>Resting Heart Rate Monitoring for Optimized Treatment and Surveillance of Hyperthyroidism</brief_title>
  <acronym>PULSAR</acronym>
  <official_title>Resting Heart Rate Monitoring for Optimized Treatment and Surveillance of Hyperthyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators want to investigate if a continuous heart rate monitoring with a wrist worn&#xD;
      fitnesstracker can be useful in the treatment and surveillance of patients suffering from&#xD;
      Graves' disease.The aim of our research project is two-fold: First, to evaluate the use of&#xD;
      continuous heart rate monitoring as a potential substitute for hormone measurements during&#xD;
      treatment of hyperthyroidism. Second, to use continuous heart rate monitoring as a tool for&#xD;
      early detection of relapse after discontinuation of antithyroid drugs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>resting heart rate</measure>
    <time_frame>four months</time_frame>
    <description>continuous resting heart rate measurement with fitnesstracker in relation to the thyroid hormone levels in patients during and after treatment with anti-thyroid drugs.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hyperthyroidism</condition>
  <condition>Graves Disease</condition>
  <arm_group>
    <arm_group_label>Group Treatment</arm_group_label>
    <description>Patients with newly diagnosed hyperthyroidism due to Graves' disease, if anti thyroid drug treatment is planned.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Surveillance</arm_group_label>
    <description>Patients suffering from Graves' disease in whom discontinuation of the anti-thyroid therapy is planned.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Continuous heart rate monitoring</intervention_name>
    <description>Continuous heart rate monitoring with a wrist worn fitnesstracker</description>
    <arm_group_label>Group Surveillance</arm_group_label>
    <arm_group_label>Group Treatment</arm_group_label>
    <other_name>Regular measurements of thyroid hormone levels</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Graves' disease at the beginning and after cessation of anti-thyroid drug&#xD;
        treatment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All participants:&#xD;
&#xD;
          -  BMI 17 to 35 kg/m2&#xD;
&#xD;
          -  Diagnosis of Graves' disease (matching one of the following criteria: elevated TRAb&#xD;
             and/or ultrasonography and functional imaging consistent with Graves' disease)&#xD;
&#xD;
          -  In possession of a smart phone&#xD;
&#xD;
          -  Able to use a wearable device and willing to regularly upload their biometric data&#xD;
&#xD;
          -  Informed consent as documented by signature (Appendix Informed Consent Form)&#xD;
&#xD;
        Group &quot;treatment&quot;:&#xD;
&#xD;
          -  TSH &lt; 0.2 mIU/l and&#xD;
&#xD;
          -  fT4 &gt; 25 pM or fT3 &gt; 8 pM&#xD;
&#xD;
          -  ATD planned, additional treatment with propranolol allowed&#xD;
&#xD;
        Group &quot;surveillance&quot;:&#xD;
&#xD;
          -  TSH within the reference range between 0.3 and 4.5 mlU/l&#xD;
&#xD;
          -  Cessation of ATD is planned within the next 2-4 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic treatment with beta blocker or verapamil-type calcium antagonist for other&#xD;
             reason than symptomatic treatment of hyperthyroidism (propranolol)&#xD;
&#xD;
          -  Treatment with amiodarone&#xD;
&#xD;
          -  Pacemaker with continuous stimulation.&#xD;
&#xD;
          -  Severe concomitant diseases: chronic heart failure, liver cirrhosis, kidney failure,&#xD;
             active cancer&#xD;
&#xD;
          -  Abuse of alcohol or illicit drugs&#xD;
&#xD;
          -  Allergic to nickel or silicone&#xD;
&#xD;
          -  Inability to follow the procedures of the study, e.g. due to language problems,&#xD;
             psychological disorders, dementia, etc. of the participant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Claudia Maushart, MD</last_name>
    <phone>+41612652525</phone>
    <email>claudia.maushart@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthias Betz, MD</last_name>
    <email>matthias.betz@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Maushart, MD</last_name>
      <phone>+41612652525</phone>
      <email>claudia.maushart@usb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Matthias Betz, MD</last_name>
      <email>matthias.betz@usb.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>June 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart rate; Pulse rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graves Disease</mesh_term>
    <mesh_term>Hyperthyroidism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

